EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combined impact of first-trimester risk and aspirin adherence on preterm preeclampsia prevention

Daniel L Rolnik, Min Yi Tan, Argyro Syngelaki, David Wright, Liona C Poon, Kypros H Nicolaides, ASPRE and SPREE Collaborators

American Journal of Obstetrics and Gynecology · 2026

DOI: 10.1016/j.ajog.2026.02.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Obstetrics and Gynecology, 2026. Verfasst von Daniel L Rolnik und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia. Electronic address: daniel.rolnik@monash.edu. Hauptthemen laut MEDLINE: Aspirin, Pre-Eclampsia, Platelet Aggregation Inhibitors, Drug Monitoring. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fetal Medicine Foundation, FP7 Health, National Institute for Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Aspirin prevents preterm preeclampsia in high-risk pregnancies, but the extent to which its effectiveness depends on adherence and baseline risk remains uncertain. OBJECTIVE: To evaluate how first-trimester preeclampsia risk and aspirin adherence jointly influence aspirin's preventive effect, and to assess the potential benefits and harms of targeted versus universal prophylaxis. STUDY DESIGN: We combined data from the Aspirin for Evidence-based Preeclampsia Prevention and the Screening Program for Preeclampsia cohorts, including singleton pregnancies delivering at ≥24 weeks. All pregnancies were screened for preterm preeclampsia at 11+0 to 13+6 weeks using the Fetal Medicine Foundation competing risks model, which combines maternal characteristics, mean arterial pressure, uterine artery pulsatility index, and serum placental growth factor. Aspirin adherence and baseline risk distributions were modeled using Monte Carlo simulations to estimate relative risk, absolute risk reduction, and number needed to treat under 4 adherence scenarios: full (100%), trial-based (intention-to-treat), 50%, and variable adherence positively correlated with predicted risk (ρ=0.4). Decision-curve analysis assessed net benefit across risk thresholds. RESULTS: Simulations informed by 51,024 pregnancies indicated that aspirin's preventive effect varied substantially with adherence. In fixed-adherence scenarios, the strongest effect occurred with full adherence (relative risk 0.25, 95% confidence interval 0.09-0.66) and the weakest with 50% adherence (relative risk 0.70, 95% confidence interval 0.58-0.98). Under variable adherence, relative risk decreased nonlinearly with baseline risk, approaching the per-protocol effect in high-risk women but near null in low-risk women. Absolute risk reduction and number needed to treat were highly dependent on predicted risk: at 1 in 50 to 1 in 100 risks, number needed to treat ranged from 73 to 146 with high adherence and 161 to 321 with 50% adherence, whereas at lower risks, numbers needed to treat exceeded several thousand even with high adherence. Decision-curve analysis indicated that targeted prophylaxis using the Fetal Medicine Foundation model provided greater net benefit than universal treatment, primarily by avoiding unnecessary interventions. CONCLUSION: Aspirin is highly effective for preventing preterm preeclampsia in women at increased risk, but its effect depends on predicted risk and adherence. The absolute benefit of treatment is negligible in low-risk populations. A targeted screen-and-treat strategy using the Fetal Medicine Foundation model maximizes clinical benefit while minimizing unnecessary treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinPre-EclampsiaPlatelet Aggregation InhibitorsDrug MonitoringMedication AdherenceHumansFemalePregnancyPregnancy Trimester, FirstAdultRisk AssessmentUterine ArteryPlacenta Growth FactorMonte Carlo MethodPulsatile Flow

Stichwörter der Autor:innen

FMFPEadherenceaspirinpredictionpreeclampsiapreventionrisk

Substanzen

AspirinPlatelet Aggregation InhibitorsPlacenta Growth Factor

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia. Electronic address: daniel.rolnik@monash.edu.
  • St. Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Fetal Medicine Research Institute, King's College Hospital, London, UK.
  • Department of Clinical and Biomedical Science, University of Exeter, Exeter, UK.
  • Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR, China.

Förderung

  • Fetal Medicine Foundation
  • FP7 Health
  • National Institute for Health Research
  • King's College Hospital NHS Foundation Trust
  • National Health and Medical Research Council
  • Seventh Framework Programme
  • Medical Research Council
  • Collaboration for Leadership in Applied Health Research and Care - Greater Manchester

Zitieren

APA

Rolnik, D. L., Tan, M. Y., Syngelaki, A., Wright, D., Poon, L. C., Nicolaides, K. H., & ASPRE and SPREE Collaborators (2026). Combined impact of first-trimester risk and aspirin adherence on preterm preeclampsia prevention. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2026.02.014

Vancouver

Rolnik DL, Tan MY, Syngelaki A, Wright D, Poon LC, Nicolaides KH, et al. Combined impact of first-trimester risk and aspirin adherence on preterm preeclampsia prevention. American Journal of Obstetrics and Gynecology. 2026. doi:10.1016/j.ajog.2026.02.014

BibTeX
@article{Rolnik2026,
  author = {Rolnik, Daniel L and Tan, Min Yi and Syngelaki, Argyro and Wright, David and Poon, Liona C and Nicolaides, Kypros H and ASPRE and SPREE Collaborators, ASPRE and SPREE Collaborators},
  title = {Combined impact of first-trimester risk and aspirin adherence on preterm preeclampsia prevention},
  journal = {American Journal of Obstetrics and Gynecology},
  year = {2026},
  doi = {10.1016/j.ajog.2026.02.014}
}
Kostenlos starten →